PMV Pharmaceuticals, Inc. (PMVP)
NASDAQ: PMVP · Real-Time Price · USD
1.050
-0.030 (-2.78%)
Apr 25, 2025, 4:00 PM EDT - Market closed
Company Description
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer.
It’s lead product candidate is rezatapopt, an orally available small molecule that potently and selectively correct p53 misfolding caused by p53 mutation, Y220C, while sparing wild-type p53.
The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013.
PMV Pharmaceuticals, Inc. was incorporated in 2013 and is based in Princeton, New Jersey.
PMV Pharmaceuticals, Inc.
| Country | United States |
| Founded | 2013 |
| IPO Date | Sep 25, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 47 |
| CEO | David Mack |
Contact Details
Address: 400 Alexander Park Drive, Suite 301 Princeton, New Jersey 08540 United States | |
| Phone | 609 642 6670 |
| Website | pmvpharma.com |
Stock Details
| Ticker Symbol | PMVP |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $18.00 |
| CIK Code | 0001699382 |
| CUSIP Number | 69353Y103 |
| ISIN Number | US69353Y1038 |
| Employer ID | 46-3218129 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. David H. Mack Ph.D. | Co-Founder, Chief Executive Officer, President and Director |
| Dr. Arnold J. Levine Ph.D. | Co-Founder, Director and Member of Scientific Advisory Board |
| Dr. Deepika Jalota Pharm.D. | Chief Development Officer |
| Michael Carulli | Chief Financial Officer |
| Robert Ticktin J.D. | General Counsel, Chief Operating Officer and Company Secretary |
| Tim Smith | Senior Vice President and Head of Corporate Development and Investor Relations |
| Crystal Zuckerman | Vice President of Human Resources |
| Dr. Binh Vu Ph.D. | Senior Vice President of Drug Discovery and CMC |
| Dr. Marc Fellous M.D. | Senior Vice President and Head of Clinical Development and Medical Affairs |
| Laura De Leon | Vice President and Head of Clinical Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 25, 2025 | ARS | Filing |
| Apr 25, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 25, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 8, 2025 | SCHEDULE 13G | Filing |
| Mar 3, 2025 | 10-K | Annual Report |
| Mar 3, 2025 | 8-K | Current Report |
| Feb 21, 2025 | SCHEDULE 13G | Filing |
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |
| Feb 10, 2025 | SCHEDULE 13G | Filing |